Survival of patients with metastatic breast cancer: twenty-year data from two SEER registries.
Survival of patients with metastatic breast cancer: twenty-year data from two SEER registries.
复制标题
DOI：
10.1186/1471-2407-4-60
复制
发表时间：
2004-09-02
期刊：
影响因子：
3.8
通讯作者：
Vlastos G
中科院分区：
文献类型：
--
作者：
Tai P;Yu E;Vinh-Hung V;Cserni G;Vlastos G
许多研究人员有兴趣知道社区中转移性乳腺癌的近期治疗结果是否有任何改善，特别是10年或15年生存率。在1981年和1985年之间，782和580名女性转移性乳腺癌患者分别从康涅狄格州和旧金山-奥克兰登记处的监测，流行病学和最终结果（SEER）数据库中提取。回顾性验证了估计生存率的对数正态统计方法，因为可以使用标准生命表精算方法计算15年病因特异性生存率。估计费率与2000年的精算数据作了比较。在1991年和1995年之间，进一步752和632名女性转移性乳腺癌患者分别从康涅狄格州和旧金山-奥克兰注册。分析2005年以前的15年生存率。选择5年（1981-1985），并将患者作为一个队列随访3年。康涅狄格和旧金山-奥克兰两个登记处的估计15年病因特异性生存率分别为7.1%（95%置信区间，CI，1.8-12.4）和9.1%（95% CI，3.8-14.4）。由于SEER数据库提供到2000年底的后续信息，因此可以进行精算计算以确认（验证）估计数。Kaplan-Meier计算的15年病因特异性生存率分别为8.3%（95%CI，5.8-10.8）和7.0%（95%CI，4.3-9.7）。使用1991-1995年5年期队列并随访3年，康涅狄格州和旧金山-奥克兰两个登记处的15年病因特异性生存率估计分别为9.1%（95%CI，3.8-14.4）和14.7%（95%CI，9.8-19.6）。在1981-1985年期间，康涅狄格州和旧金山-奥克兰登记处的15年病因特异性生存率相当。在1991-1995年期间，康涅狄格州登记患者的生存率没有太大变化，但旧金山-奥克兰登记患者的生存率有所改善。
Many researchers are interested to know if there are any improvements in recent treatment results for metastatic breast cancer in the community, especially for 10- or 15-year survival. Between 1981 and 1985, 782 and 580 female patients with metastatic breast cancer were extracted respectively from the Connecticut and San Francisco-Oakland registries of the Surveillance, Epidemiology, and End Results (SEER) database. The lognormal statistical method to estimate survival was retrospectively validated since the 15-year cause-specific survival rates could be calculated using the standard life-table actuarial method. Estimated rates were compared to the actuarial data available in 2000. Between 1991 and 1995, further 752 and 632 female patients with metastatic breast cancer were extracted respectively from the Connecticut and San Francisco-Oakland registries. The data were analyzed to estimate the 15-year cause-specific survival rates before the year 2005. The 5-year period (1981–1985) was chosen, and patients were followed as a cohort for an additional 3 years. The estimated 15-year cause-specific survival rates were 7.1% (95% confidence interval, CI, 1.8–12.4) and 9.1% (95% CI, 3.8–14.4) by the lognormal model for the two registries of Connecticut and San Francisco-Oakland respectively. Since the SEER database provides follow-up information to the end of the year 2000, actuarial calculation can be performed to confirm (validate) the estimation. The Kaplan-Meier calculation for the 15-year cause-specific survival rates were 8.3% (95% CI, 5.8–10.8) and 7.0% (95% CI, 4.3–9.7) respectively. Using the 1991–1995 5-year period cohort and followed for an additional 3 years, the 15-year cause-specific survival rates were estimated to be 9.1% (95% CI, 3.8–14.4) and 14.7% (95% CI, 9.8–19.6) for the two registries of Connecticut and San Francisco-Oakland respectively. For the period 1981–1985, the 15-year cause-specific survival for the Connecticut and the San Francisco-Oakland registries were comparable. For the period 1991–1995, there was not much change in survival for the Connecticut registry patients, but there was an improvement in survival for the San Francisco-Oakland registry patients.